Apply for Brukinsa (Zanubrutinib) Copay Assistance

Brukinsa copay assistance means outside financial help that can lower what you pay for Brukinsa (zanubrutinib). Depending on your insurance, that help may come from a manufacturer copay card, the manufacturer’s patient assistance program, or a grant from an independent charitable foundation. According to BeOne, eligible patients with commercial insurance may pay $0 per prescription.*

QuickRx Specialty Pharmacy does the legwork for you. Our patient navigators check your insurance, look for the options you may qualify for, prepare and submit the applications on your behalf, and keep track of renewals, at no cost to you.*

To get started, call QuickRx at (917) 830-2525 or complete the form on this page.

*Eligibility, benefit amounts and availability are set by each manufacturer or foundation, not by QuickRx. Not all patients qualify, and programs may change or close without notice. QuickRx does not issue copay cards; we apply on your behalf.

Each program sets its own rules. Manufacturer copay cards are generally limited to patients with commercial or private insurance. Federal guidance from the HHS Office of Inspector General explains that manufacturer copay coupons cannot be used by patients whose drug is paid for by federal health care programs such as Medicare or Medicaid.

Patients with Medicare, Medicaid or no insurance may still have options, such as the manufacturer’s patient assistance program or an independent foundation grant for their condition. These usually have their own requirements, such as income and insurance documents.

QuickRx reviews your situation and tells you which options you may qualify for. Call (917) 830-2525 to get started.

Source: HHS Office of Inspector General, Special Advisory Bulletin: Pharmaceutical Manufacturer Copayment Coupons (September 2014).

*Eligibility, benefit amounts and availability are set by each manufacturer or foundation, not by QuickRx. Not all patients qualify, and programs may change or close without notice. QuickRx does not issue copay cards; we apply on your behalf.

BeOne Medicines, the maker of Brukinsa, runs a program called myBeOne Support. According to BeOne, eligible patients with commercial insurance may pay $0 per prescription, up to an annual maximum that BeOne sets.*

Manufacturer copay coupons generally cannot be used by patients whose prescription is paid for by a federal health care program such as Medicare or Medicaid. For patients with Medicare, VA, DoD or TRICARE, BeOne says it provides information on independent charitable organizations.

Manufacturer program details are from BeOne Medicines’ public myBeOne Support web pages, accessed September 30, 2026. BeOne sets and may change its own terms, benefit limits and eligibility; QuickRx is not affiliated with BeOne Medicines.

Source: HHS Office of Inspector General, Special Advisory Bulletin: Pharmaceutical Manufacturer Copayment Coupons (September 2014).

BeOne lists a free product option through myBeOne Support for patients who are prescribed Brukinsa and meet its financial criteria, which include household income limits for uninsured and underinsured patients. BeOne sets and may change these limits.*

QuickRx can help you understand your options. Call (917) 830-2525.

Manufacturer program details are from BeOne Medicines’ public myBeOne Support web pages, accessed September 30, 2026. BeOne sets and may change its own terms, benefit limits and eligibility; QuickRx is not affiliated with BeOne Medicines.

No. There is never any cost for QuickRx’s copay assistance services. You will not receive a bill from QuickRx for checking your eligibility, preparing applications, or handling renewals.*

*Eligibility, benefit amounts and availability are set by each manufacturer or foundation, not by QuickRx. Not all patients qualify, and programs may change or close without notice. QuickRx does not issue copay cards; we apply on your behalf.

No. Lexidrug lists no generic zanubrutinib available in the United States as of September 2026. Brukinsa is the only US brand.

Source: Lexidrug, zanubrutinib monograph, Generic Available (US) (accessed 9/30/2026). Availability may change.

Lexidrug lists an Average Wholesale Price (AWP) of $157.44 per 80 mg capsule and $333.46 per 160 mg tablet. At the labeled dose of 320 mg a day, 30 days works out to about $18,893 in capsules or about $20,008 in tablets at AWP.*

What you actually pay depends on your insurance and any help you may qualify for. Call (917) 830-2525 for a free benefits check.

AWP (Average Wholesale Price) is a Medi-Span benchmark published in Lexidrug (zanubrutinib monograph, accessed 9/30/2026). It is a reference price only, not a retail price, not a quote and not what you will pay. 30-day figures are simple math at the labeled 320 mg daily dose, for illustration only.

Brukinsa (zanubrutinib) is an oral cancer medicine called a Bruton tyrosine kinase (BTK) inhibitor. It was first approved by the FDA on November 14, 2019. In adults, it is approved to treat:

Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL); Waldenström macroglobulinemia; mantle cell lymphoma after at least 1 prior therapy; relapsed or refractory marginal zone lymphoma after at least 1 anti-CD20-based treatment; and relapsed or refractory follicular lymphoma after 2 or more treatments, taken together with obinutuzumab.

Source: Lexidrug, zanubrutinib monograph (last updated 8/3/2026, accessed 9/30/2026); Brukinsa prescribing information, BeOne Medicines USA, July 2026. This is not a complete list. Do not start, stop or change how you take Brukinsa without talking to your oncologist.

The usual adult dose is 160 mg twice a day or 320 mg once a day, taken until the disease progresses or side effects become too hard to manage. It can be taken with or without food.

Capsules (80 mg): swallow whole with water; do not open, break or chew. Tablets (160 mg): swallow whole with water; do not chew or crush; the tablet may be split in half. If you miss a dose, take it as soon as you can the same day, then go back to your normal schedule the next day. Avoid grapefruit, grapefruit juice and Seville oranges.

Always follow the exact dose your oncologist gives you.

Source: Lexidrug, zanubrutinib monograph (last updated 8/3/2026, accessed 9/30/2026); Brukinsa prescribing information, BeOne Medicines USA, July 2026. This is not a complete list. Do not start, stop or change how you take Brukinsa without talking to your oncologist.

Kidney: no dose change is needed when CrCl is 15 mL/minute or higher. The labeling has not studied CrCl below 15 or dialysis, though Lexidrug notes a change is unlikely because very little leaves the body in urine.

Liver: no change for mild or moderate liver problems (Child-Pugh A or B). For severe liver problems (Child-Pugh C), the dose is reduced to 80 mg twice a day. If liver injury from the drug is suspected, it is held, and it is stopped if confirmed.

Source: Lexidrug, zanubrutinib monograph (last updated 8/3/2026, accessed 9/30/2026); Brukinsa prescribing information, BeOne Medicines USA, July 2026. This is not a complete list. Do not start, stop or change how you take Brukinsa without talking to your oncologist.

In adults, common side effects include upper respiratory infections (27% to 44%), muscle and bone pain (26% to 45%), bleeding of any kind (24% to 42%), rash (20% to 29%), bruising (16% to 24%), tiredness (13% to 31%), diarrhea (14% to 22%), high blood pressure (14% to 19%), pneumonia (12% to 18%) and cough (11% to 16%). Lab changes such as low white blood cells, low platelets and high blood sugar are also common.

Call your doctor right away for signs of infection, bleeding you cannot stop, black or bloody stools, chest pain or an irregular heartbeat, fainting, yellow skin or eyes, or signs of stroke.

Source: Lexidrug, zanubrutinib monograph (last updated 8/3/2026, accessed 9/30/2026); Brukinsa prescribing information, BeOne Medicines USA, July 2026. This is not a complete list. Do not start, stop or change how you take Brukinsa without talking to your oncologist.

Bleeding: serious and fatal bleeding has occurred; the risk may be higher with blood thinners or antiplatelet medicines.

Infections: serious infections, including pneumonia and hepatitis B reactivation, have occurred.

Heart rhythm problems: atrial fibrillation, atrial flutter and ventricular arrhythmias have occurred.

Low blood counts, liver injury and second cancers: severe low blood counts, serious liver injury and new cancers (most often non-melanoma skin cancer) have been reported. Use sun protection.

Surgery: your team may pause Brukinsa for 3 to 7 days before and after surgery, depending on bleeding risk.

Source: Lexidrug, zanubrutinib monograph (last updated 8/3/2026, accessed 9/30/2026); Brukinsa prescribing information, BeOne Medicines USA, July 2026. This is not a complete list. Do not start, stop or change how you take Brukinsa without talking to your oncologist.

Yes. Strong CYP3A4 inducers should be avoided because they lower Brukinsa levels. Strong and moderate CYP3A4 inhibitors raise Brukinsa levels, so the dose is lowered (to 80 mg once a day or 80 mg twice a day). Blood thinners and antiplatelet medicines may raise the risk of bleeding. Live vaccines should be avoided.

Tell every doctor and pharmacist about every medicine, supplement and herbal product you take. QuickRx pharmacists can review your list; call (917) 830-2525.

Source: Lexidrug, zanubrutinib monograph (last updated 8/3/2026, accessed 9/30/2026); Brukinsa prescribing information, BeOne Medicines USA, July 2026. This is not a complete list. Do not start, stop or change how you take Brukinsa without talking to your oncologist.

Your care team will check your blood counts regularly and your liver tests at the start and during treatment. They will watch for bleeding, infection and heart rhythm problems, check for new skin or other cancers, and may screen for hepatitis B before you start.

Source: Lexidrug, zanubrutinib monograph (last updated 8/3/2026, accessed 9/30/2026); Brukinsa prescribing information, BeOne Medicines USA, July 2026. This is not a complete list. Do not start, stop or change how you take Brukinsa without talking to your oncologist.

Brukinsa may harm an unborn baby. Pregnancy should be checked before starting. Patients who could become pregnant, and patients whose partners could become pregnant, should use effective birth control during treatment and for 1 week after the last dose. Breastfeeding is not recommended during treatment and for 2 weeks after the last dose.

Source: Lexidrug, zanubrutinib monograph (last updated 8/3/2026, accessed 9/30/2026); Brukinsa prescribing information, BeOne Medicines USA, July 2026. This is not a complete list. Do not start, stop or change how you take Brukinsa without talking to your oncologist.

In clinical trials, about half of patients were 65 or older, and no major differences in effectiveness were seen. Patients 65 and older did have more serious side effects than younger patients, so your team may watch you more closely.

Source: Lexidrug, zanubrutinib monograph (last updated 8/3/2026, accessed 9/30/2026); Brukinsa prescribing information, BeOne Medicines USA, July 2026. This is not a complete list. Do not start, stop or change how you take Brukinsa without talking to your oncologist.

Store capsules and tablets at room temperature, 20°C to 25°C (68°F to 77°F). Brief exposure to 15°C to 30°C (59°F to 86°F) is allowed.

Source: Lexidrug, zanubrutinib monograph (last updated 8/3/2026, accessed 9/30/2026); Brukinsa prescribing information, BeOne Medicines USA, July 2026. This is not a complete list. Do not start, stop or change how you take Brukinsa without talking to your oncologist.